"The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.
Multiple myeloma is a form of blood cancer that arises from plasma cells, a type of white blood cell, found in "...
Oncaspar Patient Information including How Should I Take
In this Article
- What is pegaspargase (Oncaspar)?
- What are the possible side effects of pegaspargase (Oncaspar)?
- What is the most important information I should know about pegaspargase (Oncaspar)?
- What should I discuss with my health care provider before receiving pegaspargase (Oncaspar)?
- How is pegaspargase given (Oncaspar)?
- What happens if I miss a dose (Oncaspar)?
- What happens if I overdose (Oncaspar)?
- What should I avoid while receiving pegaspargase (Oncaspar)?
- What other drugs will affect pegaspargase (Oncaspar)?
- Where can I get more information?
What should I discuss with my health care provider before receiving pegaspargase (Oncaspar)?
Do not receive this medication if you are allergic to pegaspargase, or if you have ever been treated with asparaginase (Elspar) and had:
- a serious allergic reaction;
- a stroke or blood clot; or
- problems with your pancreas.
Before receiving pegaspargase, tell your doctor if you are allergic to any drugs, or if you have:
- diabetes (pegaspargase can raise blood sugar); or
- a bleeding or blood clotting disorder such as hemophilia.
If you have any of these conditions, you may not be able to receive pegaspargase, or you may need a dosage adjustment or special tests during treatment.
FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.
It is not known whether pegaspargase passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
How is pegaspargase given (Oncaspar)?
Pegaspargase is given as an injection through an IV needle placed into a vein, or as a shot into a muscle. You will receive this injection in a clinic or hospital setting. The IV medicine must be given slowly, and it can take up to 2 hours to complete.
After receiving this medication, your doctor may want to observe you for at least 1 hour to make sure the medication does not cause harmful side effects.
Before you receive your first treatment with this medication, you may need a skin test to make sure you are not allergic to pegaspargase.
Pegaspargase can lower the blood cells that help your body fight infections. This can make it easier for you to bleed from an injury or get sick from being around others who are ill. To be sure your blood cells do not get too low, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.
This medication can cause you to have unusual results with certain thyroid tests. Tell any doctor who treats you that you are receiving pegaspargase.
Additional Oncaspar Information
- Oncaspar Drug Interactions Center: pegaspargase inj
- Oncaspar Side Effects Center
- Oncaspar Overview including Precautions
- Oncaspar FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.